Olon Spa

About Olon Spa

Olon Group is a global leader in the development and production of active pharmaceutical ingredients for CDMO and Generics, a reliable and preferential partner to the pharmaceutical, biotech, and specialty ingredients markets. With a 2021’s turnover of 580 Mio$, OLON supplies 300 APIs for the Generic market.

Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 300 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS.

Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA) and Shanghai (China).

Read more Show less
Certifications
  • CE
  • FDA
    FDA
  • GMP
  • ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IT
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
Contract Service
Engineering
Manufacturer/Innovator
Contact info
  • +39 02 9523.1
  • Strada Rivoltana KM 6/7, 20090, Rodano (Milan), Italy
Show contact info Hide contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Frankfurt, Germany
1-3 November 2022
View Exhibitor Profile

Products from Olon Spa (5)

  • Active Pharmaceutical Ingredients

    Product Active Pharmaceutical Ingredients

    OLON is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).

    Always considering human safety and environmental security, OLON handles...
  • Fermentation

    Product Fermentation

    Relying on an experience gained over more than 50 years, OLON represent one of the most extensive know how of microbial fermentation in Europe. The Group, global leader in biomanufacturing, has two Biotechnology Centres located in Italy and is one of the first companies in Italy producing via microbial fe...
  • Highly Potent Pharmaceutical Principles

    Product Highly Potent Pharmaceutical Principles

    Olon relies on one of the most extensive expertise in handling highly potent pharmaceutical principles at global level, has raised the level of containment up to the actual standards and very large scale putting in place a set of primary and secondary containment designed to avoid the active substances di...
  • Choline Fenofibrate

    Product Choline Fenofibrate

    Olon SpA offers a wide range of products which includes choline fenofibrate. Therapeutic class: antilipemic. Contact us for more information.
  • Ciclopirox

    Product Ciclopirox

    Olon SpA offers a wide range of products which includes ciclopirox. Therapeutic class: antimicotic. Contact us for more information.

Olon Spa Resources (3)

  • Olon Presenting a Significant Expansion of APIs Pipeline for Olon Group

    News Olon Presenting a Significant Expansion of APIs Pipeline for Olon Group

    CPHI WORLDWIDE,

    A SIGNIFICANT EXPANSION OF APIs PIPELINE FOR OLON GROUP

    8 Nov 2021
  • Company Presentation

    Brochure Company Presentation

  • An introduction to Pharmaceuticals in the Environment (PiE) and Anti-Microbial Resistance (AMR)

    Video An introduction to Pharmaceuticals in the Environment (PiE) and Anti-Microbial Resistance (AMR)

    Pharmaceuticals in the environment (PiE) are an important issue and the subject of increasing focus by the media, governments, NGOs and the wider public. Human and veterinary medicines bring enormous societal benefits, supporting public health and ensuring a safe food supply. One of the unintended but inevitable results of delivering life-changing medicines to patients is that pharmaceutical residues can find their way into the environment. Most are a result of patient and veterinary use and the inappropriate disposal of unused medicines. Unintended release of pharmaceuticals in manufacturing emissions represents a minor yet potentially important environmental source that is controllable and has the potential to be further minimised. This session will provide a practical introduction to the topic aimed at pharmaceutical and healthcare professionals Session in partnership with PSCI (pscinitiative.org) This presentation was originally aired as part of the CPHI Festival of Pharma.